NYSE:TEVATeva Pharmaceutical Industries Stock Price, Forecast & News

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TEVA shares have increased by 31.0% and is now trading at $11.80.
View which stocks have been most impacted by Coronavirus.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 4 sell ratings, 12 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) released its quarterly earnings data on Thursday, May, 7th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.59 by $0.17. The business earned $4.36 billion during the quarter, compared to the consensus estimate of $4.15 billion. Teva Pharmaceutical Industries had a negative net margin of 4.73% and a positive return on equity of 18.10%. The company's quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.60 earnings per share.
View Teva Pharmaceutical Industries' earnings history.

Teva Pharmaceutical Industries updated its FY20 earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of $2.30-2.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.44. The company issued revenue guidance of $16.6-17.0 billion, compared to the consensus revenue estimate of $16.74 billion.

22 brokerages have issued 12 month price targets for Teva Pharmaceutical Industries' shares. Their forecasts range from $8.00 to $16.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $11.67 in the next year. This suggests that the stock has a possible downside of 1.1%.
View analysts' price targets for Teva Pharmaceutical Industries.

Press coverage about TEVA stock has been trending somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.
View the latest news about Teva Pharmaceutical Industries.

Some companies that are related to Teva Pharmaceutical Industries include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Royalty Pharma (RPRX), UCB (UCBJF), Genmab A/S (GMAB), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Catalent (CTLT), GRIFOLS S A/S (GRFS) and GALAPAGOS NV/S (GLPG).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), NVIDIA (NVDA), AT&T (T), Alibaba Group (BABA), Bank of America (BAC), Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Cisco Systems (CSCO) and Walt Disney (DIS).

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries' stock is owned by many different retail and institutional investors. Top institutional shareholders include Harel Insurance Investments & Financial Services Ltd. (0.70%), Sumitomo Mitsui Trust Holdings Inc. (0.38%), Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (0.31%), Strs Ohio (0.07%), Raymond James & Associates (0.05%) and Raymond James Financial Services Advisors Inc. (0.04%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Iris Beck Codner, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Sol J Barer and Sven Dethlefs.
View institutional ownership trends for Teva Pharmaceutical Industries.

TEVA stock was sold by a variety of institutional investors in the last quarter, including Psagot Investment House Ltd., Personal Resources Investment & Strategic Management Inc., Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Cambridge Investment Research Advisors Inc., Strs Ohio, Raymond James & Associates, Dfpg Investments LLC, and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, and Richard Daniell.
View insider buying and selling activity for Teva Pharmaceutical Industries.

TEVA stock was bought by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd., SG Americas Securities LLC, Centric Wealth Management, Janney Montgomery Scott LLC, Atalanta Sosnoff Capital LLC, Nisa Investment Advisors LLC, Spouting Rock Asset Management LLC, and MERIAN GLOBAL INVESTORS UK Ltd.
View insider buying and selling activity for Teva Pharmaceutical Industries.

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TEVA stock can currently be purchased for approximately $11.80.

Teva Pharmaceutical Industries has a market capitalization of $12.89 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 40,039 workers across the globe.

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]